Basilea has entered a discovery partnership with Phare Bio to develop novel antibiotics using Phare’s generative AI platform. Under the agreement, Phare Bio will design antibacterial molecules aligned with a predefined target product profile using its generative AI platform. Basilea will assume downstream development of the selected molecules, with Phare Bio eligible for predefined success-based payments.
The collaboration combines AI-driven discovery with Basilea’s anti-infectives expertise and represents a rapidly emerging strategy for early drug discovery and innovation. We believe this latest development is aligned with Basilea’s strategy to strengthen its development pipeline for long-term sustained growth.
Industrials | Comment
Industrials | Comment
Industrials | Comment
Consumer | Comment